Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy)
Open Access
- 1 July 2020
- journal article
- research article
- Published by Future Medicine Ltd in Future Oncology
- Vol. 16 (20), 1425-1432
- https://doi.org/10.2217/fon-2020-0369
Abstract
Background: We describe cancer patients with coronavirus disease-2019 (COVID-19) infection treated at the Piacenza's general hospital (north Italy). Materials & methods: 25 cancer patients infected by COVID-19 admitted at the Piacenza's general hospital from 21 February to 18 March 2020. Outcome from the infection were compared with infected noncancer patients. Results: 20 patients (80%) were treated with antiviral therapy and hydroxychloroquine and five (20%) received hydroxychloroquine alone. Nine (36%) patients died, while 16 (64%) overcome the infection. In the control group the mortality was 16.13% and the overcome from infection was 83.87%. Conclusion: Mortality for COVID-19 was greater in cancer patients when compared with noncancer patients, worse prognosis for older age, women and patients treated with hydroxychloroquine alone. However, the comparisons did not reach statistical significance in most cases. This could be due to the small sample size that is the main limitation of the study.This publication has 14 references indexed in Scilit:
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive studyThe Lancet Infectious Diseases, 2020
- First imported case of 2019 novel coronavirus in Canada, presenting as mild pneumoniaThe Lancet, 2020
- Cancer patients in SARS-CoV-2 infection: a nationwide analysis in ChinaThe Lancet Oncology, 2020
- Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor bindingThe Lancet, 2020
- Myeloid suppressor cells in cancer and autoimmunityJournal of Autoimmunity, 2017
- Features of Postoperative Immune Suppression Are Reversible With Interferon Gamma and Independent of Interleukin-6 PathwaysAnnals of Surgery, 2016
- Selective Depletion of Regulatory T Cell Subsets by Docetaxel Treatment in Patients with Nonsmall Cell Lung CancerJournal of Immunology Research, 2014
- Nosocomial infections in patients with cancerThe Lancet Oncology, 2009
- Comparison of procalcitonin and C-reactive protein as markers of sepsisCritical Care Medicine, 2003